• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Jubilant Therapeutics Appoints Chief Scientific Officer

    Iontas and Fair Journey Biologics Partner with Quell Therapeutics

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Vetter Establishes Office in China

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Alcami

    Cytovance Biologics

    PCI Pharma Services

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Aphena Pharma Solutions

    PCI Pharma Services

    Almac Group

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    API to ADC: A Journey Through High Potency

    This class of compounds represents a major advance in oncology research and treatment application.

    API to ADC: A Journey Through High Potency
    Related CONTENT
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Catalent Pharma Solutions
    • Regis Custom Pharma
    • Softweb Solutions
    Maurits Janssen, Head Commercial Development API, Lonza Pharma & Biotech09.16.19
    In the development of new cancer therapies, molecules have become more potent, and their structures, physical properties and final dosage forms have simultaneously become more complex. Most of these highly potent oncology small molecule drugs are dosed systematically to patients, thereby affecting non-diseased tissue along with the targeted cancer cells.

    The introduction of the antibody drug conjugate (ADC), a relatively new class of cancer therapy compounds that combine cytotoxic small molecule payloads with antibodies, can lessen the impact to non-diseased areas in comparison to systemic administration of highly potent small molecule products. While still systematically admitted, the antibody functionality guides the toxic payload directly to the diseased cells, effectively producing a very focused and concentrated dosing specific to the diseased area. This class of compounds represents a major advance in oncology research and treatment application.

    These drugs, combining the potency of highly potent API (HPAPI) and a biologic targeting agent, are now gradually finding their way to the market. The ADC market has grown consistently by double digits since 2012 (17%), according to an analysis by Citeline (July 2017), and there are five ADCs currently approved for commercial use.

    Given the commonality of high potency between ADCs and HPAPI products, there will be considerable similarities in their manufacturing and product development best practices. A few examples of these similarities include the importance of operator safety when handling potent chemicals; access to flexible manufacturing assets; and the ability to scale up from drug substance to drug product manufacturing.

    However, there are also important differences. ADCs require technologies from the large molecule toolbox including handling, purification and formulation. Furthermore, ADC drug products are often administered via injectable dosing whereas many HPAPI are dosed orally.

    These insights will be especially useful for smaller biotech companies, which control around 80% of all new chemical entities (NCEs) in today’s drug development pipeline but often do not have development or production assets of their own. Such companies may benefit from working with an outsourced partner with specialized experience and capabilities, in order to access flexible and phase-appropriate infrastructure to bring the next innovative ADC product from concept to commercialization.

    Importance of containment when working with potent compounds
    Since HPAPIs and ADCs are very potent compounds, best practices for HPAPI handling and containment can be applied as general lessons for the pharma and biotech industry when it comes to safe manufacturing of ADC products and their toxic payloads.

    In the HPAPI small molecule field, the main challenge is to maintain product containment in pharmaceutical production areas within the required low levels, in order to ensure employee safety. However, whereas the containment range for highly potent small molecule APIs typically suffices between 0.1-10 µg/m3 (OEL), ADC payload containment regimes must typically be 10-100 times stricter due to the increased potency of the payload.

    Pharmaceutical manufacturers may approach containment in several ways. Most western countries have legislation that requires employees be able to work in normal protective clothing (lab coat & safety goggles). Containment should primarily be achieved by technical (design) measures and, to a lesser extent, by organizational measures to ensure no one relies solely on personal protective equipment.

    With plant setup, there are several technical solutions for achieving containment. The primary containment components—including reactors, centrifuge/filter and dryer—have to be tightly closed and robust. Connections between equipment are traditionally hard-piped, though the quality of connections has since improved to the level that flexible connections are gaining use.

    Meanwhile, process-related containment challenges generally relate to the addition of raw materials, sampling of reaction mass/product (e.g. during drying) and cleaning of the equipment at the end of production. For the addition or removal of material during production, several packaging solutions and valves are available on the market, and some are easier to use with better quality of containment than others. In addition, any waste stream needs to be managed as strictly as the product itself.

    Finally, it is critical that HPAPI and payload handling be performed by a team of experienced and properly trained personnel. Training is crucial for introducing new processes in the facility or new members to a team, but fostering a culture of flawless execution is imperative. Even with the right equipment and best procedures, at least half of performance relates to the workforce in a specific plant or company.

    The bottom line is that an integrated employee safety and containment strategy, combined with proactive cleaning and decontamination processes, including during technical transfer—within a culture of flawless execution—facilitates ongoing efficient and safe manufacturing operations and, ultimately, contribute to lower costs for highly potent compounds.

    Managing uncertainties with phase-appropriate production scales
    Small molecule APIs can be manufactured in a variety of manners to accommodate for scale. Pharma and biotech companies can benefit from choosing an outsourced production partner with a wide and scalable chemical toolbox and able to support the entire product lifecycle from development through market launch, and into efficient commercialization. Working with partners with scalable production assets—inclusive of containment—can lead to time and cost savings during both clinical and commercial production.

    In addition, having phase-appropriate manufacturing scales allows pharma companies and CDMOs to anticipate uncertainties encountered during clinical development. It is not uncommon for companies to expect to need extremely large volumes of their drug product, only to have the demand fail to materialize. This is increasingly the case for more specialized products which are becoming the norm in the era of personalized medicine.

    This difficulty in projecting demand often means that there is a mismatch between the scale of production equipment expected—defining batch size and thus regulatory relevance—and what is actually necessary. A more realistic challenge of forecasts versus production assets, and especially batch size, will lead to much more economical production costs. Flexibility in assets is increasingly important so that demand swings can be rapidly accommodated.

    In such cases that product volumes grow above current production asset capabilities, pharma companies may benefit from working with an external provider that can scale up quickly and seamlessly. In this scenario, validation to a larger concept can be initiated while keeping the same supplier and same production site. This can also substantially lower the risk and costs associated with regulatory change and maintain supply from being interrupted. Of course, this is true for both small molecule APIs as well as for biologics, and especially applicable for highly potent applications where more specialized approaches are required.

    A lower-risk option has been demonstrated with dedicated production facilities, e.g.  Lonza’s monoplant approach. We developed a dedicated HPAPI manufacturing line for Clovis Oncology for their Rucaparib drug for the treatment of ovarian cancer. By dedicating the line, it allowed a high level of process automation and implementation of real time release testing (RTRT), thus lowering operational costs substantially. In addition, this dedicated line can run 24/7 and 365 days a year and can be achieved with surprisingly smaller scale manufacturing equipment (e.g. reactor size 1’000L)—thereby also lowering capital costs substantially.

    By having buffer stock of non-potent intermediates, production can start up immediately upon customer product demand, thus allowing for delivery in record time. Ultimate customer value of security of supply was thus guaranteed, and the possibility of a market shortage has been successfully mitigated. Cost of goods also fell substantiality compared to pre-monoplant production campaigns, due to increased flexibility and the holistic approach.

    Formulation: Advantage of integrated services
    Following adoption of the optimal manufacturing capacity for the drug substance, the next step is to consider production of the drug product. Particle engineering of HPAPI, e.g. particle size reduction or spray drying, may be required to address dissolution rate or solubility issues. Specialized dosage forms that minimize HPAPI handling during processing and/or better ensure low dose uniformity can come into play, e.g. liquid filled hard capsule technology. Similar considerations as apply to the HPAPI are applicable for these processing steps, i.e. phase-appropriate scale, effective containment, operator experience and culture. Working with a single external provider for drug substance and drug product development to commercialization can introduce synergies and reduce timelines, risk and costs for biopharma companies.

    Typically, when working with separate partners, the released drug substance is sent to a drug product manufacturer who performs analyses on the incoming goods and carries the product through further processing. Both transportation and control of incoming goods take time and do not add value, beyond risk mitigation on behalf of the formulator. However, when working with different entities, the time spent on those non-value add activities cannot be avoided as all parties have the responsibility to have proper processes in place. 

    Other activities where the alignment of drug substance to product manufacturing is rather inefficient include information exchange between different partners in the value chain, alignment and coordination of responsibilities and the respective contractual or quality agreements. The net result is prolonged timelines and costs that can be especially problematic to smaller biopharma companies, especially for drug programs with orphan or break-through designations where speed is paramount.  

    A Tufts University report concludes that a single source partner has the potential to shorten timelines by an average of 19 weeks for a small molecule through phase I, with an estimated reduction in program costs of nearly $21 million.

    Differences to keep in mind between ADCs and small molecule HPAPI
    Despite many similarities, there are important differences between ADCs and small molecule HPAPIs which influence manufacturing processes that biopharmaceutical companies need to keep in mind.
    First of all, small molecule manufacturing uses a broad toolbox of often aggressive reactions, forcing the need of high capital investment in glass-lined, stainless steel equipment. For ADCs, the manufacturing processes are often water-based or use dilute organic solvent in aqueous-based buffer, and the coupling reaction happens under mild conditions (e.g., to avoid deterioration of the antibody).

    However, the main difference for ADCs is the fact that different toxin platforms exist, including maytansines, auristatins, among others where the very strict cleaning requirements (i.e., demonstrating equipment is clean at nano-levels) often lead to the selection of platform-dedicated process equipment. This adds substantial costs to the overall infrastructure, thus impacting the cost of goods.

    Because of these high capital costs, there is a growing trend of using disposable, single-use equipment for ADC processing. Although this has not yet become routine for commercial, long-term larger-scale manufacturing, this may change over time for therapeutic indications with small patient populations.

    Strengths in ADC production
    ADCs are typically produced as bulk drug substance (BDS) that have a similar composition as the final formulation. Therefore, one could think that integration of these would add limited value. However, in this value chain using the same supplier for both intermediates and drug product relieves the drug developer of the risks associated with intermediate supply and management of the integrated timeline.
    Lonza is able produce and assemble the separate parts of ADC products at a single facility in Visp, Switzerland. This straightforward setup not only reduces cost and time savings specific to scalable capabilities and reduces material transfer and coordination between separate producers, but it can also lead to easier regulatory processes and filing, since all manufacturing occurs under the same quality systems. The track record from the Visp site includes more than 300 commercial large-scale batches and currently three commercial ADCs.

    In addition to providing an integrated model of drug substance and drug product manufacturing across its API and biologic facilities globally, starting in 2020, Lonza will be capable of delivering monoclonal antibodies from the IBEX facility in Visp, the site of drug product manufacturing. That means that all ADC raw materials will be available at the same location, further simplifying the regulatory processes and reducing the manufacturing timeline. Transfer of the antibody from Lonza’s global manufacturing network will no longer be required.

    Conclusion
    The market for ADCs and HPAPI products in general has more potential than ever, a trend that is bound to continue in the future. That said, there are several important challenges that biopharmaceutical companies will need to overcome. Obstacles include: more complex, highly potent molecules; the ongoing shift to personalized medicine; accelerated timelines to market; and uncertain in-market demand. These challenges can be especially daunting for small and emerging companies.

    For companies of all sizes, there may be benefit in working with an adept external partner with a wide set of scalable capabilities. Integrated services and innovative business models are increasingly coming into play. As the ADC market continues to grow, new ways of collaboration will help bring ingenuity and greater efficiencies to the table in order to deliver innovative, life-saving therapies to patients. 


    Maurits Janssen is Head of Commercial Development, API Manufacturing & Development at Lonza Pharma & Biotech. He is based in Basel, Switzerland.
    Related Searches
    • orphan
    • drying
    • Dosage
    • quality
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    Regis Custom Pharma Regis Custom Pharma
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Adare Pharma Solutions Adare Pharma Solutions
    Continued and Consistent Investment in Manufacturing Facilities Continued and Consistent Investment in Manufacturing Facilities
    Highly Potent Expansions Highly Potent Expansions
    High Containment & Cost Savings with Single Use Isolator Technology High Containment & Cost Savings with Single Use Isolator Technology
    Lonza, Celltrion Sign Contract to Manufacture Remsima Drug Substance Lonza, Celltrion Sign Contract to Manufacture Remsima Drug Substance
    Omeros, Lonza Enter Commercial Manufacturing Agreement Omeros, Lonza Enter Commercial Manufacturing Agreement
    Lonza, Vineti Enter Cell and Gene Therapy Network Alliance Lonza, Vineti Enter Cell and Gene Therapy Network Alliance
    Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved
    FLAMMA Acquires Teva’s Philadelphia cGMP Facility FLAMMA Acquires Teva’s Philadelphia cGMP Facility

    Related Features

    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • APIs | Cytotoxics and High Potency Manufacturing
      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21

    • APIs
      Small Molecule API CDMO: A Capital Intensive Business?

      Small Molecule API CDMO: A Capital Intensive Business?

      Exploring small molecule API market trends.
      Dr. Michele Jermini and Dr. Enrico Polastro, Contributing Writers 03.01.21


    • Serialization
      Serialization: Level 5 Solution

      Serialization: Level 5 Solution

      Why a Level 5 solution is required for small pharma companies to fully harness serialization investment.
      Steve Wood, President & CEO, Covectra 03.01.21

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    Trending
    • Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement For Novavax’ COVID-19 Vaccine
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • Pharmaron Acquires Biomanufacturing Site In The UK From AbbVie
    Breaking News
    • Jubilant Therapeutics Appoints Chief Scientific Officer
    • Iontas and Fair Journey Biologics Partner with Quell Therapeutics
    • Vetter Establishes Office in China
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Diets High In Fructose Could Cause Immune System Damage
    Nestlé Acquires Premium Water Brand Essentia
    Kaneka Probiotics Announces Launch of L. plantarum DR7
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs First OTC Home Molecular COVID-19 Test
    FDA Approves Second Sight's Argus 2s Retinal Prosthesis
    Cross Border Venture Financing Rose in Final Quarter of 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sharp Appoints EU Qualified Person
    Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine
    Metrics Contract Services Completes Russian Regulatory Inspection
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    It's International Women's Day—But What Does That Mean?
    e.l.f. Cosmetics and Chipotle Collaborate on Burrito-Inspired Makeup Collection
    Weekly Recap: Sephora Expansion, Ulta Partners with Loop, International Women’s Day & More
    Happi

    Latest Breaking News From Happi

    Cococare Appoints First Woman President
    Ross Highlights Triple Shaft Mixers
    Arm & Hammer Unveils Foot Wipes
    Ink World

    Latest Breaking News From Ink World

    Capital Printing Invests in 2nd Komori Press
    Arna Marketing Adds Canon’s ProStream, VarioPRINT iX Production Inkjet Presses
    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Xeikon details upcoming Xeikon Café TV seminars
    Resource Label Group acquires New England Label
    UV+EB-cured products rated 'easier to recycle'
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Arm & Hammer Launches Foot Wipes
    Kimberly-Clark Names Chief Research and Development Officer
    FPInnovations Develops Biodegradable Mask
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Australia Clears Conformis' iTotal PS Knee Replacement System
    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Wearable Patch Market to Reach $27.8 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login